Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 13, 2013 - Issue 2
Submit an article Journal homepage
83
Views
3
CrossRef citations to date
0
Altmetric
Theme: Stroke - Review

Use of intravenous recombinant tissue plasminogen activator in patients outside the defined criteria: safety and feasibility issues

Karl Matz Department of Clinical Neurosciences and Preventive Medicine, Danube University Krems, Krems, Austria. [email protected]
&
Michael Brainin Department of Clinical Neurosciences and Preventive Medicine, Danube University Krems, Krems, Austria
Pages 177-185 | Published online: 09 Jan 2014

References

  • Lansberg MG, Albers GW, Wijman CA. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc. Dis. 24(1), 1–10 (2007).
  • Kaste M. Approval of alteplase in Europe: will it change stroke management? Lancet Neurol. 2(4), 207–208 (2003).
  • Hacke W, Kaste M, Bluhmki E et al.; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 359(13), 1317–1329 (2008).
  • Ringelstein EB, Meckes-Ferber S, Hacke W, Kaste M, Brainin M, Leys D; European Stroke Initiative executive committee. European Stroke Facilities Survey: the German and Austrian perspective. Cerebrovasc. Dis. 27(2), 138–145 (2009).
  • Sandercock P, Wardlaw JM, Lindley RI et al.; IST-3 collaborative group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 379(9834), 2352–2363 (2012).
  • De Keyser J, Gdovinová Z, Uyttenboogaart M, Vroomen PC, Luijckx GJ. Intravenous alteplase for stroke: beyond the guidelines and in particular clinical situations. Stroke 38(9), 2612–2618 (2007).
  • Meretoja A, Putaala J, Tatlisumak T et al. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke 41(7), 1450–1458 (2010).
  • Karlinski M, Kobayashi A, Litwin T et al.; SITS Poland Collaborative Group. Intravenous thrombolysis for acute ischaemic stroke in patients not fully adhering to the European licence in Poland. Neurol. Neurochir. Pol. 46(1), 3–14 (2012).
  • The SITS-EAST Collaborative Group. Intravenous alteplase in ischemic stroke patients not fully adhering to the current drug license in Central and Eastern Europe. Int. J. Stroke (2012).
  • Guillan M, Alonso-Canovas A, Garcia-Caldentey J et al. Off-label intravenous thrombolysis in acute stroke. Eur. J. Neurol. 19(3), 390–394 (2012).
  • Breuer L, Blinzler C, Huttner HB, Kiphuth IC, Schwab S, Köhrmann M. Off-label thrombolysis for acute ischemic stroke: rate, clinical outcome and safety are influenced by the definition of ‘minor stroke’. Cerebrovasc. Dis. 32(2), 177–185 (2011).
  • Cronin CA, Shah N, Morovati T, Hermann LD, Sheth KN. No increased risk of symptomatic intracerebral hemorrhage after thrombolysis in patients with European Cooperative Acute Stroke Study (ECASS) exclusion criteria. Stroke 43(6), 1684–1686 (2012).
  • The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333(24), 1581–1587 (1995).
  • Hacke W, Kaste M, Fieschi C et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS-II). Second European–Australasian Acute Stroke Study Investigators. Lancet 352(9136), 1245–1251 (1998).
  • Hacke W, Kaste M, Fieschi C et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 274(13), 1017–1025 (1995).
  • Wardlaw JM, Murray V, Berge E et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 379(9834), 2364–2372 (2012).
  • Davis SM, Donnan GA, Parsons MW et al.; EPITHET investigators. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 7(4), 299–309 (2008).
  • Perini F, De Boni A, Marcon M, Bolgan I, Pellizzari M, Dionisio LD. Systolic blood pressure contributes to intracerebral haemorrhage after thrombolysis for ischemic stroke. J. Neurol. Sci. 297(1–2), 52–54 (2010).
  • Butcher K, Christensen S, Parsons M et al.; EPITHET Investigators. Postthrombolysis blood pressure elevation is associated with hemorrhagic transformation. Stroke 41(1), 72–77 (2010).
  • Mokin M, Kass-Hout T, Kass-Hout O, Zivadinov R, Mehta B. Blood pressure management and evolution of thrombolysis-associated intracerebral hemorrhage in acute ischemic itroke. J. Stroke Cerebrovasc. Dis. 21(8), 852–859 (2012).
  • Yong M, Kaste M. Association of characteristics of blood pressure profiles and stroke outcomes in the ECASS-II trial. Stroke 39(2), 366–372 (2008).
  • Ahmed N, Wahlgren N, Brainin M et al.; SITS Investigators. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke – International Stroke Thrombolysis Register (SITS-ISTR). Stroke 40(7), 2442–2449 (2009).
  • Martin-Schild S, Hallevi H, Albright KC et al. Aggressive blood pressure-lowering treatment before intravenous tissue plasminogen activator therapy in acute ischemic stroke. Arch. Neurol. 65(9), 1174–1178 (2008).
  • Adams HP Jr, del Zoppo G, Alberts MJ et al.; American Heart Association; American Stroke Association Stroke Council; Clinical Cardiology Council; Cardiovascular Radiology and Intervention Council; Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 38(5), 1655–1711 (2007).
  • Bruno A, Levine SR, Frankel MR et al.; NINDS rt-PA Stroke Study Group. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 59(5), 669–674 (2002).
  • Yong M, Kaste M. Association of characteristics of blood pressure profiles and stroke outcomes in the ECASS-II trial. Stroke 39(2), 366–372 (2008).
  • Poppe AY, Majumdar SR, Jeerakathil T, Ghali W, Buchan AM, Hill MD; Canadian Alteplase for Stroke Effectiveness Study Investigators. Admission hyperglycemia predicts a worse outcome in stroke patients treated with intravenous thrombolysis. Diabetes Care 32(4), 617–622 (2009).
  • Demchuk AM, Morgenstern LB, Krieger DW et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke 30(1), 34–39 (1999).
  • Tanne D, Kasner SE, Demchuk AM et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation 105(14), 1679–1685 (2002).
  • Ribo M, Molina C, Montaner J et al. Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients. Stroke 36(8), 1705–1709 (2005).
  • Matz K, Keresztes K, Tatschl C et al. Disorders of glucose metabolism in acute stroke patients: an underrecognized problem. Diabetes Care 29(4), 792–797 (2006).
  • Committee for Medicinal Products for Human Use: summary information on a refferal opinion following an arbitration pursutant to arcticle 29 of directive 2001/83/EC, for actilyse CPMP/3346/02, 21 November 2002.
  • Arnold M, Mattle S, Galimanis A et al. Impact of admission glucose and diabetes on recanalization and outcome after intra-arterial thrombolysis for ischaemic stroke. Int. J. Stroke doi:10.1111/j.1747-4949.2012.00879.x (2012) (Epub ahead of print).
  • Wahlgren N, Ahmed N, Eriksson N et al.; Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy Investigators. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST). Stroke 39(12), 3316–3322 (2008).
  • Mishra NK, Ahmed N, Davalos A et al.; SITS and VISTA collaborators. Thrombolysis outcomes in acute ischemic stroke patients with prior stroke and diabetes mellitus. Neurology 77(21), 1866–1872 (2011).
  • Fuentes B, Martínez-Sánchez P, Alonso de Leciñana M et al.; Madrid Stroke Network. Diabetes and previous stroke: hazards for intravenous thrombolysis? Eur. J. Neurol. 19(4), 587–593 (2012).
  • Prabhakaran S, Rivolta J, Vieira JR et al. Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke. Arch. Neurol. 67(5), 559–563 (2010).
  • Matute MC, Masjuan J, Egido JA et al. Safety and outcomes following thrombolytic treatment in stroke patients who had received prior treatment with anticoagulants. Cerebrovasc. Dis. 33(3), 231–239 (2012).
  • Vergouwen MD, Casaubon LK, Swartz RH et al.; Investigators of the Registry of the Canadian Stroke Network. Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator. Stroke 42(4), 1041–1045 (2011).
  • Ruecker M, Matosevic B, Willeit P et al. Subtherapeutic warfarin therapy entails an increased bleeding risk after stroke thrombolysis. Neurology 79(1), 31–38 (2012).
  • Xian Y, Liang L, Smith EE et al. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA 307(24), 2600–2608 (2012).
  • Lee VH, Conners JJ, Prabhakaran S. Intravenous thrombolysis in a stroke patient taking dabigatran. J. Stroke Cerebrovasc. Dis. 21(8), 916.e11–916.e12 (2012).
  • Brunner F, Tomandl B, Schröter A et al. Hemorrhagic complications after systemic thrombolysis in acute stroke patients with abnormal baseline coagulation. Eur. J. Neurol. 18(12), 1407–1411 (2011).
  • Diedler J, Ahmed N, Sykora M et al. Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. Stroke 41(2), 288–294 (2010).
  • Fiehler J, Albers GW, Boulanger JM et al.; MR STROKE Group. Bleeding risk analysis in stroke imaging before thromboLysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. Stroke 38(10), 2738–2744 (2007).
  • Sheth KN, Shah N, Morovati T, Hermann LD, Cronin CA. Intravenous rt-PA is not associated with increased risk of hemorrhage in patients with intracranial aneurysms. Neurocrit. Care 17(2), 199–203 (2012).
  • de Leciñana MA, Fuentes B, Masjuan J et al. Thrombolytic therapy for acute ischemic stroke after recent transient ischemic attack. Int. J. Stroke 7(3), 213–218 (2012).
  • De Silva DA, Manzano JJ, Chang HM, Wong MC. Reconsidering recent myocardial infarction as a contraindication for IV stroke thrombolysis. Neurology 76(21), 1838–1840 (2011).
  • Willey JZ, Stillman J, Rivolta JA et al. Too good to treat? Outcomes in patients not receiving thrombolysis due to mild deficits or rapidly improving symptoms. Int. J. Stroke 7(3), 202–206 (2012).
  • Smith EE, Abdullah AR, Petkovska I, Rosenthal E, Koroshetz WJ, Schwamm LH. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke 36(11), 2497–2499 (2005).
  • Nedeltchev K, Schwegler B, Haefeli T et al. Outcome of stroke with mild or rapidly improving symptoms. Stroke 38(9), 2531–2535 (2007).
  • Helsinki Stroke Thrombolysis Registry Group. Intravenous thrombolysis for acute ischemic stroke patients presenting with mild symptoms. Int. J. Stroke doi:10.1111/j.1747-4949.2012.00808.x (2012) (Epub ahead of print).
  • Parsons MW, Christensen S, McElduff P et al.; Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) Investigators. Pretreatment diffusion- and perfusion-MR lesion volumes have a crucial influence on clinical response to stroke thrombolysis. J. Cereb. Blood Flow Metab. 30(6), 1214–1225 (2010).
  • Hacke W, Donnan G, Fieschi C et al.; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363(9411), 768–774 (2004).
  • Dávalos A, Cendra E, Genís D, López-Pousa S. The frequency, characteristics and prognosis of epileptic seizures at the onset of stroke. J. Neurol. Neurosurg. Psychiatr. 51(11), 1464 (1988).
  • Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C. Epileptic seizures after a first stroke: the Oxfordshire Community Stroke Project. BMJ 315(7122), 1582–1587 (1997).
  • Kent DM, Selker HP, Ruthazer R, Bluhmki E, Hacke W. The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke 37(12), 2957–2962 (2006).
  • Tsivgoulis G, Saqqur M, Barreto A et al. Validity of HAT score for predicting symptomatic intracranial hemorrhage in acute stroke patients with proximal occlusions: data from randomized trials of sonothrombolysis. Cerebrovasc. Dis. 31(5), 471–476 (2011).
  • Mazya M, Egido JA, Ford GA et al.; SITS Investigators. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: Safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke 43(6), 1524–1531 (2012).
  • Menon BK, Saver JL, Prabhakaran S et al. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Stroke 43(9), 2293–2299 (2012).
  • Saposnik G, Fang J, Kapral MK et al.; Investigators of the Registry of the Canadian Stroke Network (RCSN); Stroke Outcomes Research Canada (SORCan) Working Group. The iScore predicts effectiveness of thrombolytic therapy for acute ischemic stroke. Stroke 43(5), 1315–1322 (2012).
  • Strbian D, Meretoja A, Ahlhelm FJ et al. Predicting outcome of IV thrombolysis-treated ischemic stroke patients: the DRAGON score. Neurology 78(6), 427–432 (2012).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.